Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(2):92-94; doi:10.1093/jnci/96.2.92
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McBride, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McBride, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Are Intellectual Property Rights Hampering Cancer Research?

Gail McBride

The first 150 words of the full text of this article appear below.

In 1988, Harvard Medical School was awarded the first of three patents for creating the first transgenic mouse that would develop a human cancer. The mouse soon became known as the "OncoMouse" and was, at the time, considered pioneering technology by the U.S. Patent Office. The achievement occurred in the laboratory of Philip Leder, M.D., with funding from E. I. DuPont de Nemours & Company; as a consequence, Harvard gave DuPont certain exclusive rights to the resulting intellectual property. The patents, issued between 1988 and 1999, cover the animal itself, the process of making it, and methods of using it.


Figure Removed (Available Only in the Full Text)
View larger version (59K):
[in this window]
[in a new window]
  		In 1988, Harvard Medical School was awarded the first of three patents for creating the first transgenic mouse that would develop a human cancer. E. I. DuPont de Nemours & Company has certain exclusive rights to the resulting intellectual property. Since then, many variations of this "OncoMouse" have been created; . . . [Full Text of this Article]

 
Transgenic Mice as a Preclinical Model

Eventual Solutions?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?